In a report released on February 11, Brian Abrahams from RBC Capital maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research ...

Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall ...

Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total ...

Explore the detailed Corbus Pharmaceuticals Holding balance sheet to understand the company’s financial health and stability. This page provides a clear breakdown of key metrics, including total ...

HC Wainwright reaffirmed their buy rating on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a research ...

Corbus Pharmaceuticals presented new data from the first Western study of its antibody-drug conjugate treatment for cancer.

Corbus Pharmaceuticals (CRBP) announced that data from its US and UK conducted first-in-human dose escalation clinical study of CRB-701 is ...

Shares of Corbus Pharmaceuticals Holdings Inc. CRBP inched 0.23% higher to $13.33 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones ...

In this article, we are going to take a look at where Corbus Pharmaceuticals Holdings ... While recent rate cuts could encourage the revival of scientific projects, analysts like Jared Holz ...

Shares of Corbus Pharmaceuticals Holdings Inc. CRBP inched 0.07% higher to $14.29 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite ...